Michael A. Tortorici

2.6k total citations · 1 hit paper
69 papers, 1.9k citations indexed

About

Michael A. Tortorici is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Michael A. Tortorici has authored 69 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 11 papers in Surgery. Recurrent topics in Michael A. Tortorici's work include Lung Cancer Treatments and Mutations (13 papers), Renal Transplantation Outcomes and Treatments (10 papers) and Renal cell carcinoma treatment (7 papers). Michael A. Tortorici is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Renal Transplantation Outcomes and Treatments (10 papers) and Renal cell carcinoma treatment (7 papers). Michael A. Tortorici collaborates with scholars based in United States, Switzerland and Australia. Michael A. Tortorici's co-authors include Samuel M. Poloyac, Patrick M. Kochanek, Yazdi K. Pithavala, Paul Bycott, Ezra E.W. Cohen, Sinil Kim, Roger B. Cohen, David R. Shalinsky, Francis P. Worden and Madeleine Kane and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael A. Tortorici

69 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

2008 494 citations Ezra E.W. Cohen, Lee S. Rosen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Michael A. Tortorici

Since Specialization

Citations

This map shows the geographic impact of Michael A. Tortorici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Tortorici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Tortorici more than expected).

Fields of papers citing papers by Michael A. Tortorici

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Tortorici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Tortorici. The network helps show where Michael A. Tortorici may publish in the future.

Co-authorship network of co-authors of Michael A. Tortorici

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Tortorici. A scholar is included among the top collaborators of Michael A. Tortorici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Tortorici. Michael A. Tortorici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CSL112 (APOLIPOPROTEIN A-I [HUMAN]) SIMILARLY ENHANCES CHOLESTEROL EFFLUX CAPACITY IN JAPANESE AND CAUCASIAN SUBJECTS: FINDINGS FROM A PHASE 1 STUDY 2021 ·Journal of the American College of Cardiology ·Michael A. Tortorici, Regina Clementi, (unknown), (unknown), Danielle Duffy, (unknown), (unknown), John W. Roberts	2
2	Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency 2019 ·International Immunopharmacology ·Ying Zhang, (unknown), Hugo Chapdelaine, (unknown), Mikhail Rojavin, Michael A. Tortorici, Élie Haddad	10
3	Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials 2018 ·Journal of Clinical Immunology ·Stephen Jolles, Mikhail Rojavin, John‐Philip Lawo, Robert P. Nelson, Richard L. Wasserman, Michael Borte, Michael A. Tortorici, Kohsuke Imai, Hirokazu Kanegane	21
4	Abstract 16500: CSL112 Restores Cholesterol Efflux in Patients Immediately After Acute Myocardial Infarction 2017 ·Circulation ·Andreas Gille, Samuel D. Wright, Michael A. Tortorici, Danielle Duffy, (unknown), Megan K. Yee, Lawrence I. Deckelbaum, Denise D’Andrea, C. Michael Gibson	3
5	Population pharmacokinetics of recombinant coagulation factor VIII‐SingleChain in patients with severe hemophilia A 2017 ·Journal of Thrombosis and Haemostasis ·(unknown), John Roberts, Michael A. Tortorici, Alex Veldman, Katie St. Ledger, Annette Feussner, (unknown)	33
6	Axitinib plasma pharmacokinetics and ethnic differences 2015 ·Investigational New Drugs ·Ying Chen, (unknown), Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala	23
7	Pharmacokinetics of single-agent axitinib across multiple solid tumor types 2014 ·Cancer Chemotherapy and Pharmacology ·Michael A. Tortorici, Ezra E.W. Cohen, Yazdi K. Pithavala, May Garrett, Ana Ruiz-Garcı́a, Sinil Kim, John P. Fruehauf	13
8	Kidney function assessment and its role in drug development, review and utilization 2014 ·Expert Review of Clinical Pharmacology ·Michael A. Tortorici, Thomas D. Nolin	7
9	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib 2013 ·Clinical Genitourinary Cancer ·Brian I. Rini, Thibault De La Motte Rouge, Andrea Harzstark, M. Dror Michaelson, Glenn Liu, Viktor Grünwald, Antonella Ingrosso, Michael A. Tortorici, Paul Bycott, Sinil Kim, (unknown), Robert J. Motzer	36
10	Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers 2012 ·Cancer Chemotherapy and Pharmacology ·Yazdi K. Pithavala, Ying Chen, Melvin Toh, Paulina Selaru, Robert R. LaBadie, May Garrett, Brian Hee, (unknown), (unknown), Karen J. Klamerus, Michael A. Tortorici	36
11	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers 2012 ·European Journal of Clinical Pharmacology ·Michael A. Tortorici, Virginia Parks, Kyle Matschke, Joan Korth‐Bradley, Alain Patat	7
12	Design, Conduct, Analysis, and Interpretation of Clinical Studies in Patients With Impaired Kidney Function 2012 ·The Journal of Clinical Pharmacology ·Michael A. Tortorici, David L. Cutler, Lei Zhang, Marc Pfister	11
13	Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours 2012 ·British Journal of Cancer ·Lainie P. Martin, Mark Kozloff, Roy S. Herbst, Thomas A. Samuel, (unknown), Brad Rosbrook, Michael A. Tortorici, (unknown), Jamal Tarazi, Anthony J. Olszanski, Thomas A. Rado, Alex Starr, Roger B. Cohen	21
14	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics 2011 ·European Journal of Clinical Pharmacology ·Meghan Brennan, J. Andrew Williams, Ying Chen, Michael A. Tortorici, Yazdi K. Pithavala, (unknown)	38
15	A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers 2011 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Jiang Ji, Juan Zhang, Michael A. Tortorici, Yazdi K. Pithavala, Lei Lü, (unknown), Pei Hu	17
16	Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics 2010 ·Investigational New Drugs ·Michael A. Tortorici, Melvin Toh, Sadayappan V. Rahavendran, Robert R. LaBadie, Christine Alvey, Thomas Marbury, (unknown), Matthew Green, (unknown), Brian Hee, Yazdi K. Pithavala	47
17	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study breakdown → 2008 ·Journal of Clinical Oncology ·Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes, Merrill S. Kies, Arlene A. Forastiere, Francis P. Worden, Madeleine Kane, Eric J. Sherman, Sinil Kim, Paul Bycott, Michael A. Tortorici, David R. Shalinsky, Katherine Liau, Roger B. Cohen	494
18	Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors 2007 ·Molecular Cancer Therapeutics ·Roger B. Cohen, Mark Kozloff, (unknown), Yazdi K. Pithavala, Michael A. Tortorici, Katherine Liau, Jamal Tarazi, Anthony J. Olszanski	1
19	A Model for Supporting and Training Clinical Pharmaceutical Scientist PhD Students 2007 ·American Journal of Pharmaceutical Education ·Michael A. Tortorici, Susan J. Skledar, Michael A. Zemaitis, Robert J. Weber, Randall B. Smith, Patricia D. Kroboth, Samuel M. Poloyac	2
20	Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system 2007 ·Critical Care Medicine ·Michael A. Tortorici, Patrick M. Kochanek, Samuel M. Poloyac	275

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact